Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 713Pancreatic Neoplasms 500Carcinoma, Hepatocellular 333Colonic Neoplasms 282Stomach Neoplasms 277Rectal Neoplasms 236Esophageal Neoplasms 198Neoplasms 194Liver Neoplasms 169Neoplasm Metastasis 164Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 111Cholangiocarcinoma 91Ovarian Neoplasms 87Lung Neoplasms 85Gastrointestinal Neoplasms 80Melanoma 76Gastrointestinal Stromal Tumors 68Adenocarcinoma Of Esophagus 64Adenocarcinoma 62Prostatic Neoplasms 59Biliary Tract Neoplasms 58Carcinoma, Renal Cell 56Sarcoma 54Head and Neck Neoplasms 54Urinary Bladder Neoplasms 51Gallbladder Neoplasms 49Barrett Esophagus 49Bile Duct Neoplasms 47Anus Neoplasms 47

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2 Positive Esophagogastric Cancer × Gastrointestinal × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡